Komori
Business alliance2784Alfresa Holdings CorporationTrading & Wholesale

Apocreate and 12 pharmacies enter into a business partnership to commercialize a dispensing service for veterinary hospitals

Apocreate entered into a business partnership agreement with 12薬局 to commercialize a service that receives prescription information online from veterinary hospitals and delivers the dispensed medicines. 12薬局 will provide the system and operational expertise, while Apocreate will handle dispensing and delivery.

Worth reading
41Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Agreements reached under this partnership

Business alliance
2784Alfresa Holdings Corporation
Alliance partner株式会社12薬局
Details of the alliance
  1. 1

    Licensing of the online prescription system “VMO” and service marks, among other rights

  2. 2

    Initial review of dispensing requests received by Apocreate

  3. 3

    Handling inquiries from veterinary hospitals and other parties regarding veterinary dispensing

  4. 4

    Education and support for contract-related operations concerning veterinary dispensing

  5. 5

    Collection services for veterinary dispensing payments

  6. 6

    Other operational support for the veterinary dispensing business

  7. 7

    Based on dispensing requests from veterinary hospitals, Apocreate will perform dispensing services and deliver the dispensed medicines.

These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.

About the partner
Business DescriptionOperation of veterinary dispensing pharmacies / Retail and wholesale sales of pharmaceuticals and medical supplies / Planning, development, sale and maintenance of computer systems
LocationSetagaya-ku, Tokyo
Share capital¥92 million
Impact on Business Performance

Although the impact of this matter on our consolidated results for the fiscal year ending March 2027 is expected to be minor, we believe it will contribute to enhancing the corporate value of our group over the medium to long term.

Contract Date28 August 2026Alliance start dateThe service is scheduled to launch after the necessary permits for handling veterinary pharmaceuticals have been obtained.
Agreements reached under this partnership
ItemDetails
Name of alliance partner株式会社12薬局
Alliance partner's business activitiesOperation of veterinary dispensing pharmacies, Retail and wholesale sales of pharmaceuticals and medical supplies, Planning, development, sale and maintenance of computer systems
Alliance partner's locationSetagaya-ku, Tokyo
Alliance partner's capital¥92 million
Type of allianceBusiness alliance
Details of the allianceLicensing of the online prescription system “VMO” and service marks, among other rights, Initial review of dispensing requests received by Apocreate, Handling inquiries from veterinary hospitals and other parties regarding veterinary dispensing, Education and support for contract-related operations concerning veterinary dispensing, Collection services for veterinary dispensing payments, Other operational support for the veterinary dispensing business, Based on dispensing requests from veterinary hospitals, Apocreate will perform dispensing services and deliver the dispensed medicines.
Contract Date28 August 2026
Alliance start dateThe service is scheduled to launch after the necessary permits for handling veterinary pharmaceuticals have been obtained.
Impact on Business PerformanceAlthough the impact of this matter on our consolidated results for the fiscal year ending March 2027 is expected to be minor, we believe it will contribute to enhancing the corporate value of our group over the medium to long term.
Items this document does not state (14)
Alliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionShare Acquisition Date and Payment DateChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Demand for animal healthcare and medical services is increasing as pets are increasingly regarded as family members and live longer. The partnership also aims to reduce the dispensing and inventory-management burden on veterinary hospitals, reduce waiting times and the burden of collecting medicines for pet owners, and expand the business portfolio in the animal healthcare sector.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Apocreate and 12 pharmacies enter into a business partnership to commercialize a dispensing service for veterinary hospitals | Alfresa Holdings Corporation (2784) timely disclosure | Komori